Osimertinib (Tagrisso) has a strong foothold as first-line therapy for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but resistance to the third-generation EGFR tyrosine ...

CHICAGO — Adjuvant osimertinib conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA non-small cell lung cancer, according to results of the ...

Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

First-line osimertinib improved OS compared with standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors among patients with previously untreated advanced EGFR-mutated non ...

Single-agent osimertinib and the combination demonstrated activity in tumors with MET overexpression, MET amplification, or both. The study population had a median follow-up of 8.2 months.

TAGRISSO ® (osimertinib) Important Safety Information There are no contraindications for TAGRISSO Interstitial Lung Disease (ILD)/Pneumonitis occurred in 3.5% and was fatal in 0.6% of 833 ...

Osimertinib, sold under the brand name Tagrisso, is available to patients with Stage 1B-3A lung cancer who have a certain genetic mutation and have had surgery to remove cancerous tumors.

Osimertinib has been approved since February 2016 for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small ...

Lu S, Kato T, Dong X, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Eng J Med . Published online June 2, 2024. doi: 10.1056/NEJMoa240261 ...

Osimertinib (Tagrisso, AstraZeneca) cemented its role as front-line treatment of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) in last year's FLAURA trial.

Credit: Getty Images. Osimertinib, a kinase inhibitor, is currently marketed under the brand name Tagrisso. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental ...

Osimertinib is one of the newest in a class of tyrosine kinase inhibitors (TKIs) that target the epidermal growth factor receptor (EGFR) in non–small cell lung cancer (NSCLC).